Nanobiotix S.A. (NBTX) Revenue History
Annual and quarterly revenue from 2011 to present
NBTX Revenue Over Time (2011–2025)
NBTX Revenue Growth History
8 of 14 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- -28.6%
- FY2013 revenue growth
- +64.4%
- FY2014 revenue growth
- +73.7%
- FY2015 revenue growth
- +44.9%
- FY2016 revenue growth
- +35.0%
- FY2017 revenue growth
- -31.3%
- FY2018 revenue growth
- -6.5%
- FY2019 revenue growth
- -27.0%
- FY2020 revenue growth
- -8.5%
- FY2021 revenue growth
- +13.8%
- FY2022 revenue growth
- +80.4%
- FY2023 revenue growth
- +658.1%
- FY2024 revenue growth
- -119.9%
- FY2025 revenue growth
- +512.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3.0M | +118.2% |
| Q2 2025 | $26.6M | +186.8% |
| Q4 2024 | $-16,479,000 | -150.1% |
| Q2 2024 | $9.3M | +182.1% |
| Q4 2023 | $32.9M | +854.9% |
| Q2 2023 | $3.3M | +147.8% |
| Q4 2022 | $3.4M | +159.6% |
| Q2 2022 | $1.3M | +0.8% |
Revenue Breakdown (FY 2025)
NBTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
NBTX Revenue Analysis (2011–2025)
Current Revenue & Growth
As of July 8, 2026, Nanobiotix S.A. (NBTX) generated trailing twelve-month (TTM) revenue of $22.5 million. The most recent quarter (Q4 2025) recorded $3.0 million in revenue, down 88.7% sequentially.
Historical Growth Trajectory
NBTX's 5-year compound annual growth rate (CAGR) stands at +66.4%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +83.8% exceeds the 5-year average, indicating an acceleration in the most recent period. Nanobiotix S.A.'s highest annual revenue of $36.2 million was recorded in 2023.
Revenue by Segment
NBTX's revenue is primarily driven by Services (43%), Research And Development (42%), and Other Sales (13%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including NVCR (+8.5% YoY), ARAY (-7.9% YoY), and SENS (+71.9% YoY). Compare NBTX vs NVCR →
NBTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NBTXCurrent | $22M | - | +66.4% | -36.5% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ARAY | $459M | -7.9% | +3.7% | 1.7% | |
 SENS | $35M | +71.9% | +48.1% | -193.8% | |
 ONCO | $815,371 | -61.8% | - | -778.2% |
NBTX Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $29.6M | +512.3% | $29.6M | 100.0% | $-10,818,000 | -36.5% |
| 2024 | $-7,190,000 | -119.9% | $-7,190,000 | 100.0% | $-68,392,000 | 951.2% |
| 2023 | $36.2M | +658.1% | $36.2M | 100.0% | $-26,779,000 | -74.0% |
| 2022 | $4.8M | +80.4% | $4.8M | 100.0% | $-46,702,000 | -977.8% |
| 2021 | $2.6M | +13.8% | $2.6M | 100.0% | $-52,579,000 | -1986.4% |
| 2020 | $2.3M | -8.5% | $2.3M | 100.0% | $-36,428,000 | -1566.8% |
| 2019 | $2.5M | -27.0% | $2.5M | 100.0% | $-46,779,000 | -1841.0% |
| 2018 | $3.5M | -6.5% | $3.5M | 100.0% | $-30,067,000 | -864.2% |
| 2017 | $3.7M | -31.3% | $3.7M | 100.0% | $-25,267,000 | -678.9% |
| 2016 | $5.4M | +35.0% | $5.4M | 100.0% | $-21,854,693 | -403.1% |
| 2015 | $4.0M | +44.9% | $4.0M | 100.0% | $-17,141,647 | -426.9% |
| 2014 | $2.8M | +73.7% | $2.8M | 100.0% | $-9,619,777 | -347.2% |
| 2013 | $1.6M | +64.4% | $1.6M | 100.0% | $-8,179,418 | -512.7% |
| 2012 | $971K | -28.6% | $971K | 100.0% | $-5,152,828 | -530.9% |
| 2011 | $1.4M | - | $1.4M | 100.0% | $-5,227,238 | -384.3% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBTX — Frequently Asked Questions
Quick answers to the most common questions about buying NBTX stock.
Is NBTX's revenue growth accelerating or slowing?
NBTX TTM revenue: $22M. YoY growth: N/A. 5-year CAGR: +66.4%.
What is NBTX's revenue history from 2011 to 2026?
Nanobiotix S.A. (NBTX) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $22M, growing at N/A YoY. The 5-year CAGR is +66.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NBTX's long-term revenue growth rate (CAGR)?
Nanobiotix S.A.'s 5-year revenue CAGR of +66.4% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NBTX.
Why does NBTX's quarterly revenue fluctuate?
NBTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Nanobiotix S.A.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is NBTX's revenue distributed by segment?
NBTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NBTX's revenue compare to industry peers?
Nanobiotix S.A. (NBTX) with TTM revenue of $22M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.